ABCC1 and ABCC10 as predictive biomarkers of docetaxel treatment response in prostate cancer

Simple item page
dc.contributor.authorNgesi, Nandi
dc.contributor.authorAbrahams, Beynon
dc.contributor.authorShoko, Aubrey
dc.contributor.authorSekhoacha, Mamello
dc.date.accessioned2025-04-16T09:30:42Z
dc.date.available2025-04-16T09:30:42Z
dc.date.issued2025
dc.description.abstractProstate cancer (PCa) is a leading global health burden, with a particularly high prevalence in South Africa. Despite therapeutic advancements, chemoresistance remains a major challenge, limiting the efficacy of docetaxel and contributing to treatment failure and disease progression. Multidrug resistance (MDR), primarily mediated by ATP-binding cassette (ABC) transporters such as ABCC1 and ABCC10, has been implicated in reduced chemotherapy effectiveness. This study aimed to evaluate the association between ABCC1 and ABCC10 expression levels and docetaxel treatment response in PCa patients. A retrospective case-control study was conducted using pre-treated formalin-fixed paraffin-embedded (FFPE) tissue biopsies from PCa patients. Patients were classified into good responders (cases) and poor responders (cases) based on treatment outcomes. For each patient, tumour and adjacent normal sections were excised from FFPE samples, with normal sections serving as the control group. RNA was extracted and subjected to quantitative real-time PCR (qRT-PCR) to assess ABCC1 and ABCC10 expression levels. ABCC1 and ABCC10 were significantly upregulated in tumour sections of poor responders, whereas good responders exhibited downregulated expression in tumour sections. Importantly, normal tissue sections (controls) displayed significantly lower expression levels of both transporter genes compared to tumour sections. The overexpression of ABCC1 and ABCC10 in tumour tissues, particularly in poor responders, suggests their potential role in mediating docetaxel resistance. These findings highlight ABCC1 and ABCC10 as potential predictive biomarkers for docetaxel treatment response in PCa, warranting further investigation in prospective clinical studies.
dc.description.versionAuthor(s)
dc.identifier.citationNgesi, N., Abrahams, B., Shoko, A., & Sekhoacha, M. (2025). ABCC1 and ABCC10 as predictive biomarkers of docetaxel treatment response in prostate cancer. Current Research in Pharmacology and Drug Discovery, 8(2025),100216. https://doi.org/10.1016/j.crphar.2025.100216
dc.identifier.issn2590-2571 (online)
dc.identifier.urihttps://doi.org/10.1016/j.crphar.2025.100216
dc.identifier.urihttp://hdl.handle.net/11660/13012
dc.language.isoen
dc.publisherElsevier
dc.rights.holderAuthor(s)
dc.rights.licensehttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectPCa
dc.subjectChemoresistance
dc.subjectDocetaxel
dc.subjectABC-Transporters
dc.subjectFFPE
dc.subjectQuantitative RT-PCR
dc.subjectBiomarker
dc.titleABCC1 and ABCC10 as predictive biomarkers of docetaxel treatment response in prostate cancer
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ngesi_ABCC1 and ABCC10 as predictive biomarkers_2025.pdf
Size:
4.87 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Pharmacology)